FDA Requires Eye-Risk Warnings on GLP-1 Drugs

The US Food and Drug Administration is requiring companies that make GLP-1 medicines to add information about a potential risk of reduced blood flow damaging the front part of the optic nerve, or NAION, to the drugs’ warnings and precautions. The agency said the information is intended for patients and health care providers.